Finance
US to exempt UK pharmaceuticals and ingredients under trade deal
Published by Global Banking and Finance Review
Posted on December 1, 2025
1 min readLast updated: January 20, 2026
Global Banking and Finance Review
Company
Published by Global Banking and Finance Review
Posted on December 1, 2025
1 min readLast updated: January 20, 2026
The US will exempt UK pharmaceuticals from tariffs under a new trade deal, with the UK agreeing to increase NHS medicine prices and continue US investments.
WASHINGTON, Dec 1 (Reuters) - The U.S. government on Monday said it will exempt U.K.-origin pharmaceuticals, pharmaceutical ingredients, and medical technology from current and future tariffs imposed under two U.S. laws as part of a negotiated agreement in principle.
Under the deal announced by the U.S. Trade Representative's office, the Commerce Department and the Department of Health and Human Services, Britain agreed to increase the net price paid by its National Health Service for new medicines by 25%, and to continue investments by its pharmaceutical companies in the U.S.
(Reporting by Andrea Shalal and Susan Heavey, Editing by Franklin Paul)
Pharmaceuticals are chemical compounds or drugs used to diagnose, treat, or prevent diseases in humans and animals. They can be prescription medications or over-the-counter drugs.
Pharmaceutical ingredients are the active substances used in the formulation of medications. They are essential for the efficacy and safety of the final drug product.
Explore more articles in the Finance category
